Cargando…
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we aim to evaluate whether Oncotype DX improves confidence and a...
Autores principales: | Licata, Luca, Viale, Giulia, Giuliano, Mario, Curigliano, Giuseppe, Chavez-MacGregor, Mariana, Foldi, Julia, Oke, Oluchi, Collins, Joseph, Del Mastro, Lucia, Puglisi, Fabio, Montemurro, Filippo, Vernieri, Claudio, Gerratana, Lorenzo, Giordano, Sara, Rognone, Alessia, Sica, Lorenzo, Gentilini, Oreste Davide, Cascinu, Stefano, Pusztai, Lajos, Giordano, Antonio, Criscitiello, Carmen, Bianchini, Giampaolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250312/ https://www.ncbi.nlm.nih.gov/pubmed/37291235 http://dx.doi.org/10.1038/s41523-023-00559-6 |
Ejemplares similares
-
Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017) -
Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019) -
Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022) -
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
por: Lin, Hao-Kuen, et al.
Publicado: (2023) -
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID‐19 Outbreak
por: Viale, Giulia, et al.
Publicado: (2020)